Mapping the Progress of Alzheimer’s and Parkinson’s DiseaseYoshikuni Mizuno, Abraham Fisher, Israel Hanin Springer Science & Business Media, 31 мар. 2002 г. - Всего страниц: 566 1h The 5 International Conference on the Progress in Alzheimer's Disease and Parkinson's 51 1 Disease took place from March 31 to April 5 \ 2001 in Kroto, Japan. This international 1 conference was organized as a joint Congress with the 9 International Catecholamine Symposium. A total of 1258 clinicians and researchers participated in this joint congress 1h from 38 countries in the world. This book represents the proceedings of the 5 Conference on Alzheimer's and Parkinson's disease. The International Conference on the Progress in Alzheimer's and Parkinson's disease was first launched by Professor Abraham Fisher of Israel and Professor Israel Hanin of USA. The first conference was held in Eilat, Israel in 1985. The second conference was organized in Kyoto, Japan in 1989; the third one in Chicago, USA, in 1993, and the fourth one in Eilat, Israel in 1997. The International Catecholamine Symposium (ICS) is an international meeting devoted to the development of basic as well as clinical research on catecholamines. The first Catecholamine Symposium was held in Bethesda, USA in 1958. Since then this symposium has occurred every 5 years. Professor Toshiharu Nagatsu was appointed as 1h the president of the 9 International Catecholamine Symposium, which was to be held in 200 I also in Japan. Therefore, we decided to organize a joint congress of the two meetings, because there is much overlap in research between Alzheimer's disease, Parkinson's disease, and catecholamines. We thank Professor Nagatsu very much for agreeing to organizing this joint congress. |
Результаты поиска по книге
Результаты 1 – 5 из 95
Стр. ii
Извините, доступ к содержанию этой страницы ограничен..
Извините, доступ к содержанию этой страницы ограничен..
Стр. xi
Извините, доступ к содержанию этой страницы ограничен..
Извините, доступ к содержанию этой страницы ограничен..
Стр. xii
Извините, доступ к содержанию этой страницы ограничен..
Извините, доступ к содержанию этой страницы ограничен..
Стр. xiii
... ALZHEIMER'S DISEASE CELL BIOLOGY OF AMYLOIDOGENESIS : AN OVERVIEW ....... Dennis J. Selkoe , Weiming Xia , W. Taylor Kimberly , Konstantinos Vekrellis , Dominic Walsh , William Esler , and Michael S. Wolfe ALZHEIMER'S DISEASE AS A ...
... ALZHEIMER'S DISEASE CELL BIOLOGY OF AMYLOIDOGENESIS : AN OVERVIEW ....... Dennis J. Selkoe , Weiming Xia , W. Taylor Kimberly , Konstantinos Vekrellis , Dominic Walsh , William Esler , and Michael S. Wolfe ALZHEIMER'S DISEASE AS A ...
Стр. xiv
... ALZHEIMER DISEASE : ETIOPATHOGENIC AND PHARMACOGENOMIC IMPLICATIONS ................ 59 Ramón Cacabelos FAMILIAL ALZHEIMER'S DISEASE AND BIOLOGY OF PRESENILINS PRESENILIN AND AMYLOIDOGENESIS : A STRUCTURE - FUNCTION RELATIONSHIP STUDY ...
... ALZHEIMER DISEASE : ETIOPATHOGENIC AND PHARMACOGENOMIC IMPLICATIONS ................ 59 Ramón Cacabelos FAMILIAL ALZHEIMER'S DISEASE AND BIOLOGY OF PRESENILINS PRESENILIN AND AMYLOIDOGENESIS : A STRUCTURE - FUNCTION RELATIONSHIP STUDY ...
Содержание
I | 1 |
II | 7 |
III | 13 |
IV | 19 |
V | 27 |
VI | 33 |
VIII | 39 |
IX | 45 |
LXVI | 285 |
LXVIII | 291 |
LXX | 297 |
LXXI | 301 |
LXXII | 305 |
LXXIII | 311 |
LXXIV | 315 |
LXXVI | 321 |
XII | 49 |
XIII | 59 |
XIV | 65 |
XV | 73 |
XVII | 79 |
XVIII | 85 |
XIX | 91 |
XX | 95 |
XXII | 101 |
XXIII | 105 |
XXIV | 111 |
XXV | 117 |
XXVI | 121 |
XXVIII | 127 |
XXX | 133 |
XXXII | 139 |
XXXIV | 145 |
XXXVI | 157 |
XXXVIII | 165 |
XXXIX | 171 |
XL | 177 |
XLI | 183 |
XLII | 187 |
XLIII | 193 |
XLIV | 199 |
XLVI | 205 |
XLVII | 211 |
XLVIII | 217 |
L | 223 |
LI | 229 |
LII | 235 |
LIII | 239 |
LV | 245 |
LVIII | 251 |
LIX | 259 |
LX | 265 |
LXI | 271 |
LXIII | 277 |
LXV | 281 |
LXXVII | 325 |
LXXVIII | 329 |
LXXIX | 337 |
LXXX | 343 |
LXXXI | 349 |
LXXXII | 353 |
LXXXIII | 361 |
LXXXIV | 365 |
LXXXVI | 373 |
LXXXVII | 379 |
LXXXIX | 385 |
XC | 391 |
XCI | 397 |
XCII | 403 |
XCIII | 409 |
XCV | 417 |
XCVII | 423 |
XCIX | 429 |
C | 435 |
CI | 441 |
CII | 447 |
CIII | 455 |
CV | 459 |
CVII | 463 |
CVIII | 469 |
CXII | 473 |
CXIII | 477 |
CXIV | 483 |
CXVI | 491 |
CXVIII | 497 |
CXIX | 509 |
CXXI | 513 |
CXXII | 517 |
CXXIV | 523 |
CXXVI | 531 |
CXXVII | 537 |
CXXVIII | 543 |
549 | |
Другие издания - Просмотреть все
Mapping the Progress of Alzheimer’s and Parkinson’s Disease Yoshikuni Mizuno,Abraham Fisher,Israel Hanin Ограниченный просмотр - 2002 |
Mapping the Progress of Alzheimer’s and Parkinson’s Disease Yoshikuni Mizuno,Abraham Fisher,Israel Hanin Недоступно для просмотра - 2013 |
Mapping the Progress of Alzheimer’s and Parkinson’s Disease Yoshikuni Mizuno,Abraham Fisher,Israel Hanin Недоступно для просмотра - 2012 |
Часто встречающиеся слова и выражения
a-synuclein acid activity Alzheimer Alzheimer's and Parkinson's Alzheimer's disease amyloid precursor protein Ann Neurol antibodies apoE apoptosis apoptotic Aẞ associated basal ganglia binding Biochem Biol brain cabergoline Cacabelos caspase cell death Chem cholinergic clinical cognitive cortex cortical decrease degeneration dementia deposition disorders donepezil dopaminergic dopaminergic neurons drug dyskinesias dystonia Edited by Mizuno effects exon expression factors filaments function GAGs gene genetic glial hippocampus human immunoreactivity impairment increased induced inhibition inhibitors interaction kinase Kluwer Academic/Plenum Publishers L-dopa lesions levels levodopa Lewy bodies ligands Mapping the Progress membrane molecular motor MPTP mutations neurodegenerative Neurology neurons neuroprotective Neurosci onset oxidative parkin Parkinson's disease Parkinson's Disease Edited parkinsonian pathology pathway peptide phenotype phosphorylation plaques presenilin Progress of Alzheimer's receptor role Selkoe striatal striatum studies substantia nigra suggest symptoms synaptic synuclein therapeutic therapy toxic transgenic transgenic mice treatment ubiquitin vitro vivo y-secretase